Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

News Conference News ESOC 2024

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

Todd Neale

May 21, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Michael O'Riordan

March 22, 2024

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

Advertisement

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content